Tino Bourse points to new Wegovy data showing a large cut in liver fat in patients with obesity, plus continued oral version results, as possible good news for Novo stock.
Recap by typeshit. Post by @tino_bourse on Instagram.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
11:37
A 63 year old creator walks through six months on tirzepatide and a 48 pound drop, sharing a personal account of the experience.
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
He lists what Japanese clinics advertise BPC-157, TB-500 and Epitalon for, and notes the FDA has flagged missing human safety data for several of them.
New real-world data compares two paths for cardiovascular outcomes: stepping up the semaglutide dose or moving patients over to tirzepatide.
Loading…